Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US6129913A · kind A · utility
40Cited by
5References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 19, 1997 |
| Grant date | Oct 10, 2000 |
| Priority date | — |
| Expiry date | Jun 19, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/026
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.